124 related articles for article (PubMed ID: 28002023)
1. Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
Chen JH; Zheng YL; Xu CQ; Gu LZ; Ding ZL; Qin L; Wang Y; Fu R; Wan YF; Hu CP
Biol Chem; 2017 Jun; 398(7):785-792. PubMed ID: 28002023
[TBL] [Abstract][Full Text] [Related]
2. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Gavrilov V; Lavrenkov K; Ariad S; Shany S
Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
5. HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
Li L; Mei DT; Zeng Y
Biomed Pharmacother; 2016 Dec; 84():284-290. PubMed ID: 27665474
[TBL] [Abstract][Full Text] [Related]
6. FKBP3 Promotes Proliferation of Non-Small Cell Lung Cancer Cells through Regulating Sp1/HDAC2/p27.
Zhu W; Li Z; Xiong L; Yu X; Chen X; Lin Q
Theranostics; 2017; 7(12):3078-3089. PubMed ID: 28839465
[TBL] [Abstract][Full Text] [Related]
7. VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin.
Zhang L; Wang G; Wang L; Song C; Leng Y; Wang X; Kang J
Mol Cell Biochem; 2012 Feb; 361(1-2):39-45. PubMed ID: 21959976
[TBL] [Abstract][Full Text] [Related]
8. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.
Chen RL; Wang Z; Huang P; Sun CH; Yu WY; Zhang HH; Yu CH; He JQ
Int Immunopharmacol; 2021 May; 94():107357. PubMed ID: 33715980
[TBL] [Abstract][Full Text] [Related]
9. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop.
Zhang W; Shi H; Chen C; Ren K; Xu Y; Liu X; He L
Phytomedicine; 2018 Sep; 48():51-61. PubMed ID: 30195880
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Ye P; Xing H; Lou F; Wang K; Pan Q; Zhou X; Gong L; Li D
Cancer Chemother Pharmacol; 2016 Mar; 77(3):613-21. PubMed ID: 26846508
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9.
Dong Z; Zhong Z; Yang L; Wang S; Gong Z
Cancer Lett; 2014 Feb; 343(2):249-57. PubMed ID: 24099915
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Ciardiello C; Roca MS; Noto A; Bruzzese F; Moccia T; Vitagliano C; Di Gennaro E; Ciliberto G; Roscilli G; Aurisicchio L; Marra E; Mancini R; Budillon A; Leone A
Oncotarget; 2016 Apr; 7(15):19559-74. PubMed ID: 26862736
[TBL] [Abstract][Full Text] [Related]
14. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells.
Sajadpoor Z; Amini-Farsani Z; Teimori H; Shamsara M; Sangtarash MH; Ghasemi-Dehkordi P; Yadollahi F
Appl Biochem Biotechnol; 2018 Aug; 185(4):1132-1144. PubMed ID: 29468525
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid enhances cisplatin cytotoxicity in melanoma cells.
Chodurek E; Orchel A; Gruchlik A; Aleksander E; Gołabek K; Dzierzewicz Z
Acta Pol Pharm; 2012; 69(6):1298-302. PubMed ID: 23285693
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement.
Paino F; La Noce M; Tirino V; Naddeo P; Desiderio V; Pirozzi G; De Rosa A; Laino L; Altucci L; Papaccio G
Stem Cells; 2014 Jan; 32(1):279-89. PubMed ID: 24105979
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells.
Lee SH; Nam HJ; Kang HJ; Samuels TL; Johnston N; Lim YC
Oncol Rep; 2015 Oct; 34(4):2065-71. PubMed ID: 26239260
[TBL] [Abstract][Full Text] [Related]
19. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line.
Yagi Y; Fushida S; Harada S; Kinoshita J; Makino I; Oyama K; Tajima H; Fujita H; Takamura H; Ninomiya I; Fujimura T; Ohta T; Yashiro M; Hirakawa K
J Exp Clin Cancer Res; 2010 Nov; 29(1):149. PubMed ID: 21080974
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
